The Brand Name PERIHART Has Generic Salt :: Perindopril
PERIHART Is From Company Franco I. Priced :: Rs. 434.5
PERIHART have Perindopril is comes under Sub class Anti Hypertensives of Main Class Cardiovascular System
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Anti Hypertensives
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Heart failure, Hypertension, IHD
Drug Dose ::
Adult: PO HTN As erbumine: Initial: 4 mg once daily. Patients w/ renovascular HTN, vol depletion, severe HTN: Initial: 2 mg once daily. Max: 8 mg/day. Elderly: Initially, 2 mg (as erbumine) once daily. Dose may be increased to max 8 mg (erbumine) after 1 mth if needed. Patients on diuretics: Withdraw diuretics 2 or 3 days before perindropil therapy. Resume later if required. If diuretic cannot be discontinued, an initial dose of 2 mg once daily. Max: 8 mg/day. Heart failure As erbumine: Initial: 2 mg in the morning. Increase slowly if needed. Maintenance: 4 mg/day. Stable ischaemic heart As erbumine: Initial: 4 mg once daily for 2 wk. Maintenance: 8 or 10 mg once daily. Elderly: Initially, 2 mg mg (as erbumine) once daily on the 1st wk. Renal impairment: CrCl (ml/min) <15 2 mg (as erbumine) or 2.5 mg (as arginine) on dialysis days. 15-30 2 mg (as erbumine) or 2.5 mg (as arginine) on alternate days. 30-60 2 mg (as erbumine) or 2.5 mg (as arginine) daily. Contraindication ::
History of angioedema related to previous ACE inhibitor treatment. Pregnancy (2nd/3rd trimesters).
Drug Precautions ::
History of airway surgery. Withdraw if there is significant increase in LFTs. Risk factors for hyperkalaemia; monitor potassium closely. Patients dependent on renin-angiotensin-aldosterone system; consider withdrawal in patients with progressive deterioration in renal function. Collagen vascular disease. Hypovolaemia; monitor BP with the 1st dose. Unilateral renal artery stenosis and pre-existing renal insufficiency; valvular aortic stenosis. Before, during, or immediately after anaesthesia. May impair ability to drive or operate machinery. Lactation.
Drug Side Effects ::
Headache, dizziness, sleep disorders, depression, fever, nervousness, somnolence; cough, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis; oedema, chest pain, abnormal ECG, palpitation; rash; hyperkalaemia, elevated triglycerides, menstrual disorder; nausea, diarrhoea, vomiting, dyspepsia, abdominal pain, flatulence: UTI, sexual dysfunction; increased LFTs; weakness, musculoskeletal pain, upper and lower extremity pain, hypertonia, paraesthesia; proteinuria; tinnitus, ear infection; viral infection, allergy. Potentially Fatal: Anaphylactoid reactions, angioedema.
Pregnancy category ::
Drug Mode of Action ::
Perindopril is an ACE inhibitor, which acts by inhibiting the conversion of angiotensin I to angiotensin II, reducing the activity of the sympathetic nervous system and inhibiting enzyme kininase, which is involved in the conversion of bradykinin and other substances.
Drug Interactions ::
May enhance hypotensive effect w/ diuretics. Additive hyperkalaemic effect w/ K supplements, K-sparing diuretics, and other drugs (e.g. ciclosporin, heparin, indometacin). May increase serum levels and toxicity of lithium. Antihypertensive effect may be reduced by aspirin or other NSAIDs. Coadministration w/ NSAIDs may also increase the risk of renal impairment. Increased risk of hypoglycaemia w/ antidiabetic agents. Rarely, nitritoid reactions occur w/ concomitant use of gold (sodium aurothiomalate). Potentially Fatal: Increased risk of hypotension, hyperkalaemia and changes in renal function (including acute renal failure) w/ aliskiren in patients w/ diabetes or renal impairment.